GT Biopharma (GTBP) News Today $2.57 -0.13 (-4.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.72 +0.16 (+6.03%) As of 05/30/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Stocks in play: GT Biopharma, Inc.May 19, 2025 | ca.finance.yahoo.comThis Natural Killer Treatment Could Help Transform How Cancer is TreatedMay 19, 2025 | baystreet.caGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation SignalsMay 19, 2025 | globenewswire.comGT Biopharma Inc.May 18, 2025 | marketwatch.comGT Biopharma appoints new board memberMay 17, 2025 | investing.comGT Biopharma adds Hilary Kramer to Board of DirectorsMay 15, 2025 | investing.comGT Biopharma announces private placement dealMay 14, 2025 | investing.comGT Biopharma Appoints New Member to its Board of DirectorsMay 14, 2025 | globenewswire.comGT Biopharma Issues Warrant to Cytovance for Services RenderedApril 6, 2025 | investing.comGT Biopharma files to sell 625,283 shares of common stock for holdersMarch 7, 2025 | markets.businessinsider.comGT Biopharma to Participate in the 10th Anniversary of the Innate Killer SummitMarch 4, 2025 | markets.businessinsider.comGT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy TweakFebruary 26, 2025 | msn.comGT Biopharma Announces Exercise of WarrantsFebruary 25, 2025 | globenewswire.comGT Biopharma could report Phase 1 trial data later this year, says Roth MKMFebruary 25, 2025 | markets.businessinsider.comGT Biopharma Announces Request for Withdrawal of Form S-1 Registration StatementFebruary 25, 2025 | markets.businessinsider.comGT Biopharma announces first patient dosed in Phase 1 trial of GTB-3650January 27, 2025 | markets.businessinsider.comGT Biopharma files automatic mixed securities shelfDecember 23, 2024 | msn.comGT Biopharma initiated with a Buy at Roth MKMDecember 3, 2024 | markets.businessinsider.comRoth MKM Initiates Coverage of GT Biopharma (GTBP) with Buy RecommendationDecember 3, 2024 | msn.comGT Biopharma Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comGT Biopharma (NASDAQ:GTBP) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comGT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceSeptember 26, 2024 | globenewswire.comGT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024September 24, 2024 | globenewswire.comGT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 15, 2024 | markets.businessinsider.comGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ LeukemiaJune 27, 2024 | globenewswire.comGT Biopharma Shares Rise 16% After Direct Offering PricesMay 21, 2024 | marketwatch.comGT Biopharma Announces $3.2 Mln Direct Offering Of Shares; Stock UpMay 21, 2024 | markets.businessinsider.comGT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 21, 2024 | globenewswire.comWhy Is GT Biopharma (GTBP) Stock Up 143% Today?May 20, 2024 | investorplace.comGT Biopharma, Inc. Common Stock (GTBP)May 18, 2024 | nasdaq.comRaymond W. Urbanski's Net WorthMay 16, 2024 | benzinga.comGTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024May 16, 2024 | investorplace.comGT Biopharma reports Q1 resultsMay 15, 2024 | msn.comGT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | globenewswire.comRecap: GT Biopharma Q4 EarningsMarch 27, 2024 | benzinga.comGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 26, 2024 | globenewswire.comGT Biopharma (GTBP) Price Target Increased by 2900.00% to 153.00February 25, 2024 | msn.comGTBP Feb 2024 2.500 callFebruary 14, 2024 | finance.yahoo.comTrading was temporarily halted for "GTBP" at 07:02 PM with a stated reason of "News pending."February 5, 2024 | marketbeat.comGT Biopharma, Inc. (GTBP)February 2, 2024 | finance.yahoo.comGT Biopharma Announces Reverse Stock Split UpdateFebruary 2, 2024 | msn.comGT Biopharma Stock (NASDAQ:GTBP), Short Interest ReportFebruary 2, 2024 | benzinga.comGT Biopharma, Inc. Announces 1-for-30 Reverse Stock SplitFebruary 1, 2024 | finance.yahoo.comBuy Rating for GT Biopharma: High Efficacy and Expanded Potential in Oncology TherapeuticsDecember 14, 2023 | markets.businessinsider.comLeading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of StockholdersDecember 6, 2023 | finance.yahoo.comGT Biopharma submits IND to FDA for CD33+ leukemia therapyDecember 4, 2023 | msn.comGT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ LeukemiaDecember 4, 2023 | finance.yahoo.comGT Biopharma: Strong Q3 Performance and Promising Pipeline Progression Justify Buy RatingNovember 23, 2023 | markets.businessinsider.comGT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingNovember 6, 2023 | finance.yahoo.comGT Biopharma GAAP EPS of -$0.06November 1, 2023 | msn.com Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address GTBP Media Mentions By Week GTBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTBP News Sentiment▼1.900.88▲Average Medical News Sentiment GTBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTBP Articles This Week▼10▲GTBP Articles Average Week Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Allakos News OnKure Therapeutics News Cadrenal Therapeutics News NanoViricides News Kezar Life Sciences News MiNK Therapeutics News Barinthus Biotherapeutics News KALA BIO News Eagle Pharmaceuticals News Daré Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTBP) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTBP Stock Free GTBP Stock Alerts